156 results on '"Maartense, E."'
Search Results
2. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG
3. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group
4. Prognostic value of geriatric assessment in older patients with advanced breast cancer receiving chemotherapy
5. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
6. Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study
7. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial
8. Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy
9. Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial
10. Non-Hodgkin's lymphoma in the elderly: A review with emphasis on elderly patients, geriatric assessment, and future perspectives
11. Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry
12. A multicentre, open study of docetaxel with regard to efficacy, safety, and quality of life in the treatment of patients with advanced or metastatic breast cancer who are resistant to anthracyclines.
13. Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin’slymphoma registry
14. Safety assessment of extended adjuvant endocrine therapy with letrozole; results of the randomized phase III IDEAL trial (BOOG 2006-05)
15. Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)
16. Abstract P2-09-08: Safety assessment of extended adjuvant endocrine therapy with letrozole; results of the randomized phase III IDEAL trial (BOOG 2006-05)
17. Abstract S1-04: Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)
18. Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006–05)
19. Treatment beyond Progression – Aktueller Stand der Studie
20. Comorbidity and treatment decision-making in elderly non-Hodgkin's lymphoma patients: a survey among haematologists
21. The predictive value of tumor-stroma ratio for radiological and pathological response to neoadjuvant chemotherapy in breast cancer (BC): A Dutch breast cancer trialists' group (BOOG) side-study
22. Changes in circulating vitamin D levels as a predictor for pathological response to neoadjuvant chemotherapy (NAC) in breast cancer (BC): A Dutch breast cancer trialists group (BOOG) side-study
23. Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study
24. NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC)-A Dutch Breast Cancer Trialists' Group (BOOG) study
25. Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers
26. NEO-ZOTAC: Toxicity data of a phase Ill randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC)
27. Feasibility and Toxicities Associated with PEG Doxo Versus Capecitabine as First-line Chemotherapy in Elderly Metastatic Breast Cancer (MBC) Patients; Results From the Randomized OMEGA Study of the Dutch Breast Cancer Trialists' Group (BOOG)
28. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study
29. Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational
30. 104 - Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006–05)
31. Three components of a geriatric screening determine the geriatric prognostic index (GPI) as risk profile before chemotherapy in the elderly
32. Mosaic Study: Actualization of Overall Survival (Os) with 10 Years Follow Up and Evaluation of Braf. By Gercor and Mosaic Investigators
33. Abstract P1-08-19: Changes in circulating vitamin D levels as a predictor for pathological response to neoadjuvant chemotherapy (NAC) in breast cancer (BC): A Dutch breast cancer trialists group (BOOG) side-study
34. Abstract P1-06-04: The predictive value of tumor-stroma ratio for radiological and pathological response to neoadjuvant chemotherapy in breast cancer (BC): A Dutch breast cancer trialists’ group (BOOG) side-study
35. Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
36. Abstract PD07-06: NEO-ZOTAC: Toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC)
37. Abstract P1-12-05: First-line chemotherapy with pegylated liposomal doxorubicin versus capecitabine in elderly patients with metastatic breast cancer: results of the phase III OMEGA study of the Dutch Breast Cancer Trialists' Group (BOOG)
38. 249 Feasibility and Toxicities Associated with PEG Doxo Versus Capecitabine as First-line Chemotherapy in Elderly Metastatic Breast Cancer (MBC) Patients; Results From the Randomized OMEGA Study of the Dutch Breast Cancer Trialists’ Group (BOOG)
39. High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial
40. Association between endoxifen serum concentration and predicted CYP2D6 phenotype in a prospective cohort of patients with early-stage breast cancer.
41. Abstract P6-14-05: Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment
42. 5136 Tamoxifen and exemestane adjuvant multinational (TEAM) trial; findings from the Dutch/belgian subset
43. Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study.
44. O1 Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy
45. Treatment beyond Progression – Aktueller Stand der Studie
46. Lack of Prognostic Significance of BCL2 and p53 Protein Overexpression in Elderly Patients with Diffuse Large B-cell Non-Hodgkin's Lymphoma: Results from a Population-based Non-Hodgkin's Lymphoma Registry
47. Three components of a geriatric screening determine the geriatric prognostic index (GPI) as risk profile before chemotherapy in the elderly
48. 502PD - Mosaic Study: Actualization of Overall Survival (Os) with 10 Years Follow Up and Evaluation of Braf. By Gercor and Mosaic Investigators
49. Patients’ preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?
50. Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.